Please select a community
Automation & Microfluidics
Biologics & Bioprocessing
Chemical Process Scale Up
Food & Beverage Analysis
Forensic Science & Clinical Toxicology
Genotyping & Gene Expression
LIMS & ELNs
Metabolomics & Lipidomics
Molecular & Clinical Diagnostics
Next Gen Sequencing
Stem Cells, Cellular Therapy & Biobanking
Become a Member
Add My Products
Updated Agonistic Antibody Discovery Service
Wednesday, April 22, 2015
Creative Biolabs announces the updated Agonistic Antibody Discovery Service.
Fluxion Biosciences Introduces the IsoFlux™ EMT Enrichment Kit
Saturday, April 18, 2015
New kits enables broader capture of tumor cells from blood using epithelial and mesenchymal markers.
TriStar2S LB 942 with HTRF-Technology
Thursday, April 16, 2015
The TriStar2S now also supports time resolved fluorescence energy transfer assays.
ProImmune Introduces ProSentium a Unique Peptide Sequence Database to Investigate T Cell Immune System
Wednesday, April 15, 2015
New service and extensive data collection covers vast range of antigens with high disease relevance.
Bioo Scientific Releases MaxSignal® Histamine ELISA Test Kit
Friday, April 10, 2015
ELISA to increase sensitivity of histamine detection in fish and fish meal.
New Tools and Services for Immunotherapy Discovery
Friday, March 20, 2015
New range of purified, soluble immunoreceptors involved in key signalling pathways.
arGEN-X Expands Preclinical Pipeline with ARGX-115
Wednesday, March 04, 2015
A novel simple antibody™ for cancer immunotherapy.
Dolomite's Microfluidics Technology Helping To Advance Antibody Therapeutics
Tuesday, February 17, 2015
The droplet generation system is being used to identify potential therapeutic targets.
Gyros Launches Nanoliter-scale Immunoassay System
Tuesday, February 10, 2015
Gyrolab xPlore - A more compact, cost-effective, single-CD tool at SLAS2015 Conference.
Showing Results 11 - 20 of 393
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Advertise On This Site
Terms & Conditions
©2015 Technology Networks
, all rights reserved.
Latest presentations and webinars
2,400+ scientific and medical posters
3,700+ scientific videos
JOIN TECHNOLOGY NETWORKS PREMIUM FREE!